Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience

Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience

Hypo-fractionated radiotherapy and stereotactic body radiotherapy are viable options for treatment of oligometastases. A prodrug of mitomycin-C is under clinical testing as a pegylated liposomal formulation (Promitil) with an improved safety profile over mitomycin-C. Promitil was offered to two pati...

Full description

Bibliographic Details
Main Authors: Esther Tahover, Rachel Bar-Shalom, Eli Sapir, Raphael Pfeffer, Igor Nemirovsky, Yehonatan Turner, Maya Gips, Patricia Ohana, Benjamin W. Corn, Andrew Z. Wang, Alberto A. Gabizon
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-11-01
Series:Frontiers in Oncology
Subjects:
colorectal cancer
oligometastases
liposomes
mitomycin-C
prodrug
radiotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2018.00544/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2018.00544/full

Similar Items